In a recent move at Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), Chief Technical Officer Nur Nicholson has sold a significant amount of company stock. The transactions, which took place on March 13, 2024, involved the sale of 11,220 shares in two separate trades.
The first batch of 7,768 shares was sold at a weighted average price of $57.307, with individual sale prices ranging from $56.91 to $57.75. The second batch consisted of 3,452 shares sold at a weighted average price of $58.1335, with prices varying from $57.92 to $58.34 for different trades. The total value of the shares sold by Nicholson amounted to approximately $645,837.
Following these transactions, Nicholson's ownership in Apellis Pharmaceuticals stands at 56,287 shares. The sales were executed in multiple trades, and the prices reported represent the weighted average sale price for each batch of shares.
Investors and interested parties should note that the reporting person has undertaken to provide full information regarding the number of shares sold and the prices at which the transactions were effected, upon request to the SEC staff, the issuer, or a security holder of the issuer.
Apellis Pharmaceuticals specializes in pharmaceutical preparations and has been a key player in the industry. The company's stock trades on the NASDAQ under the ticker symbol APLS. The recent stock sales by the CTO are a notable change in the executive's stake in the company.
The transactions were disclosed in a Form 4 filing with the Securities and Exchange Commission, with David Watson, attorney-in-fact for Nur Nicholson, signing off on the document on March 14, 2024.
InvestingPro Insights
As Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) navigates through a period of significant stock activity, including the recent sale by Chief Technical Officer Nur Nicholson, investors are closely monitoring the company's financial health and market performance. According to real-time data from InvestingPro, Apellis has a market capitalization of $6.81 billion, reflecting its standing in the pharmaceutical industry. Despite a notable sales growth of 425.83% over the last twelve months as of Q4 2023, the company's gross profit margin remains negative at -4.11%, indicating a challenge in converting revenues into actual profit.
InvestingPro Tips highlight that Apellis is expected to see sales growth in the current year, which could be a positive signal for investors considering the company's future revenue potential. However, the stock has recently taken a significant hit, with a one-week total price return of -8.14% and a one-month return of -14.88%. This volatility is an important consideration for shareholders and potential investors. Moreover, while the company operates with a moderate level of debt, analysts do not anticipate Apellis will be profitable this year, and it has not been profitable over the last twelve months.
For those looking to delve deeper into Apellis Pharmaceuticals' financials and stock performance, InvestingPro offers additional insights, including a total of 12 InvestingPro Tips for APLS. To access these insights and more, investors can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With the next earnings date approaching on May 2, 2024, staying informed with the latest data and expert analysis from InvestingPro could be crucial for making well-informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.